Sanofi Asks 340B Hospitals for Information on Purchases of Its Top-Selling Drug

Sanofi is reportedly asking hospitals for data relating to 340B purchases of Dupixent.
French drugmaker Sanofi has reportedly asked some hospitals for data relating to 340B purchases of a popular drug used to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: New Intervenor in Arkansas; Consolidated Cases in Maryland

Key filings and orders occurred in lawsuits challenging the 340B contract pharmacy access law in Missouri.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Organon Partially Exempts Missouri, Minnesota Providers from 340B Contract Pharmacy Restrictions

Organon partially exempted covered entities in two states from its contract pharmacy restrictions.
Organon, a spinoff of pharmaceutical giant Merck with a focus on women’s health, has partially exempted covered entities in Missouri [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

GSK Announces Refunds for 340B Overcharges

GlaxoSmithKline will refund covered entities that purchased certain formulations of a severe asthma treatment in 2022.
GlaxoSmithKline (GSK) will refund covered entities that purchased certain formulations of a severe asthma treatment medication in the third quarter [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B ESP Updates Claims Submission Policy, Stakeholders Voice Concerns About Compliance

Second Sight Solutions updated 340B ESP's terms of use on Oct. 4.
340B covered entities could soon be required to share new information—including reimbursement amounts, ship to dates and ship to locations—as [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: AstraZeneca Defends Subpoenas; Updates in Missouri, Mississippi, Maryland

Lawsuits challenging 340B contract pharmacy access laws recently heated up in Missouri, Mississippi and Maryland.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws this [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Former Pfizer Exec. Slams 340B, Says IRA Will Worsen Program in New Op-Ed 

Kirsten Axelsen, a consultant and former Pfizer executive, cautioned that the 340B program “will be even worse” under the IRA in an Aug. 13 op-ed.
A former Pfizer executive and current biopharmaceutical consultant took aim this week at what she called the “poorly managed” 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

After Failing To Disclose Conflict of Interest, JAMA Issues Correction to Piece Calling for Increased 340B Oversight and Transparency

JAMA corrected an opinion piece on the 340B program to disclose one author's drug industry ties, shortly after 340B Report reported on the omission.
Two weeks after publishing an opinion piece that called for increased 340B program oversight and provider transparency, JAMA issued a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

UPDATED: AbbVie Ends Voluntary 340B Discount Pricing for Dozens of Orphan Drugs

AbbVie will no longer offer voluntary 340B pricing on any of its orphan-designated drugs to covered entities subject to such exclusions.
AbbVie will no longer offer voluntary 340B pricing on any of its orphan-designated drugs to rural referral centers (RRC), sole [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

HRSA Seeks Public Comment On ADR Process and Required Administrative Load

HRSA is seeking stakeholder comments on the administrative burden of the updated 340B ADR process.
The Health Resources and Services Administration (HRSA) has requested public comment on how petitioners file their initial claims in the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live